Inhibitory effects of recombinant IL-4 and recombinant IL-13 on UHMWPE-induced bone destruction in the murine air pouch model

Journal of Surgical Research

Volumn 180, Issue 2, 2013, Pages

  Wang, Yang ^a   Wu, Ning Ning ^a   Mou, Yu Qin ^a   Chen, Liang ^a   Deng, Zhong Liang ^a  

^a CHONGQING MEDICAL UNIVERSITY   (China)

Author keywords

Air pouch model; Aseptic loosening; Interleukin 13; Interleukin 4; Osteolysis

Indexed keywords

OSTEOPROTEGERIN; PHOSPHATE BUFFERED SALINE; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B; RECOMBINANT INTERLEUKIN 13; RECOMBINANT INTERLEUKIN 4; ULTRA HIGH MOLECULAR WEIGHT POLYETHYLENE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE DESTRUCTION; BONE IMPLANT; CALVARIA; CELL DIFFERENTIATION; CONTROLLED STUDY; DONOR; DOWN REGULATION; DRUG EFFECT; FEMALE; HISTOPATHOLOGY; MOUSE; NONHUMAN; OSTEOBLAST; OSTEOCLAST; OSTEOLYSIS; PRIORITY JOURNAL;

ACID PHOSPHATASE; ANIMALS; CELL DIFFERENTIATION; DISEASE MODELS, ANIMAL; FEMALE; INTERLEUKIN-13; INTERLEUKIN-4; ISOENZYMES; MICE; MICE, INBRED BALB C; OSTEOCLASTS; OSTEOLYSIS; POLYETHYLENES; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR-KAPPA B; RECOMBINANT PROTEINS;

EID: 84875231481     PISSN: 00224804     EISSN: 10958673     Source Type: Journal    
DOI: 10.1016/j.jss.2012.04.016     Document Type: Article

References (32)

1. D.J. Berry, W.S. Harmsen, and M.E. Cabanela Twenty-five-year survivorship of two thousand consecutive primary Charnley total hip replacements: Factors affecting survivorship of acetabular and femoral components J Bone Joint Surg 84A 2002 171
2. J.D. Keener, J.J. Callaghan, and D.D. Goetz Twenty-five-year results after Charnley total hip arthroplasty in patients less than fifty years old: A concise follow-up of a previous report J Bone Joint Surg 85A 2003 1066
3. N. al-Saffar, J.T. Mah, and Y. Kadoya Neovascularisation and the induction of cell adhesion molecules in response to degradation products from orthopaedic implants Ann Rheum Dis 54 1995 201
4. K. Miyanishi, M.C. Trindade, and T. Ma Periprosthetic osteolysis: induction of vascular endothelial growth factor from human monocyte/macrophages by orthopaedic biomaterial particles J Bone Miner Res 18 2003 1573
5. C.T. Ritchlin, E.M. Schwarz, and R.J. O'Keefe RANK, RANKL and OPG in inflammatory arthritis and periprosthetic osteolysis J Musculoskel Neuron Interact 4 2004 276
6. S. Niida, M. Kaku, and H. Amano Vascular endothelial growth factor can substitute for macrophage colony-stimulating factor in the support of osteoclastic bone resorption J Exp Med 190 1999 293
7. M. Kaku, S. Kohno, and T. Kawata Effects of vascular endothelial growth factor on osteoclast induction during tooth movement in mice J Dent Res 80 2001 1880
8. M. Nakagawa, T. Kaneda, and T. Arakawa Vascular endothelial growth factor(VEGF) directly enhances osteoclastic bone resorption and survival of mature osteoclasts FEBS Lett 473 2000 161
9. D.L. Lacey, J.M. Erdmann, and S.L. Teitelbaum Interleukin-4, interferon-gamma, and prostaglandin E impact the osteoclastic cell-forming potential of murine bone marrow macrophages Endocrinology 136 1995 2367
10. Y. Okada, I. Morimoto, and K. Ura Short-term treatment of recombinant IL-4 rapidly inhibits bone formation in normal and ovariectomized mice Bone 22 1998 361
11. G.R. Mundy Role of cytokines in bone resorption J Cell Biochem 53 1993 296
12. C. Bizzarri, A. Shioi, and S.L. Teitelbaum Interleukin-4 inhibits bone resorption and acutely increases cytosolic Ca2+ in murine osteoclasts J Biol Chem 269 1994 13817
13. G.W. Duff Cytokines and acute phase proteins in rheumatoid arthritis Scand J Rheumatol 100 1994 9
14. Y. Abu-Amer IL-4 abrogates osteoclastogenesis through STAT6-dependent inhibition of NF-kappaB J Clin Invest 107 2001 1375
15. G. Zurawski, and J.E. de Vries Interleukin 13, an interleukin 4-like cytokine that acts on monocytes and B cells, but not on T cells Immunol Today 15 1994 19
16. A. Yamade, M. Takami, and T. Kawawa Interleukin-4 inhibition of osteoclast differentiation is stronger than that of interleukin-13 and they are equivalent for induction of osteoprotegerin production from osteoblasts Immunology 20 2007 573
17. J.L. Moreno, M. Kaczmarek, and A.D. Keegan IL-4 suppresses osteoclast development and mature osteoclast function by a STAT6-dependent mechanism: irreversible inhibition of the differentiation program activated by RANKL Blood 102 2003 1078
18. P. Palmqvist, P. Lundberg, and E. Persson Inhibition of hormone and cytokine-stimulated osteoclastogenesis and bone resorption by interleukin-4 and interleukin-13 is associated with increased osteoprotegerin and decreased RANKL and RANK in a STAT6-dependent pathway J Biol Chem 281 2006 2414
19. W. Ren, S.Y. Yang, and P.H. Wooley A novel murine model of orthopaedic wear-debris associated osteolysis Scand J Rheumatol 33 2004 349
20. Y. Bi, R.R. van de Motter, and A.A. Ragab The role of adherent endotoxin in stimulation of osteoclast differentiation by orthopaedic wear particles Trans Orthop Res Soc 45 1999 5
21. D.C. Markel, R. Zhang, and T. Shi Inhibitory effects of erythromycin on wear debris-induced VEGF/Flt-1 gene production and osteolysis Inflamm Res 58 2009 413
22. W.P. Ren, D.C. Markel, and R. Zhang Association between UHMWPE particle-induced inflammatory osteoclastogenesis and expression of RANKL, VEGF, and Flt-1 in vivo Biomaterials 27 2006 5161
23. S.Y. Yang, L. Mayton, and B. Wu Adeno-associated virus-mediated osteoprotegerin gene transfer protects against particulate polyethylene-induced osteolysis in a murine model Arthritis Rheum 46 2002 2514
24. U.H. Lerner Osteoclast formation and resorption Matrix Biol 19 2000 107
25. I.N. Holcomb, R.C. Kabakoff, and B. Chan FIZZ1, a novel cysteine-rich secreted protein associated with pulmonary inflammation, defines a new gene family EBMO J 19 2000 4046
26. S.M. Zurawski, P. Chomarat, and O. Djossou The primary binding subunit of the human interleukin-4 receptor is also a component of the interleukin-13 receptor J Biol Chem 270 1995 13869
27. M. Wills-Karp, and F.D. Finkelman Untangling the complex web of IL-4- and IL-13-mediated signaling pathways Sci Signal 1 2008 pe55
28. G. Grunig, M. Warnock, and A.E. Wakil Requirement for IL-13 independently of IL-4 in experimental asthma Science 282 1998 2261
29. C.K. Oh, G.P. Geba, and N. Molfino Investigational therapeutics targeting the IL-4/IL-13/STAT-6 pathway for the treatment of asthma Eur Respir Rev 19 2010 46
30. S.G. Kamel Mohamed, and E. Sugiyama Interleukin-4 inhibits RANKL-induced expression of NFATc1 and c-Fos: A possible mechanism for downregulation of osteoclastogenesis Biochem Biophys Res Commun 329 2005 839
31. A.C. Bendixen, N.K. Shevde, and K.M. Dienger IL-4 inhibits osteoclast formation through a direct on osteoclast precursors via peroxisome proliferator-activated receptor gamma 1 Proc Natl Acad Sci U S A 98 2001 2443
32. Y. Kim, K. Sato, and M. Asagiri Contribution of nuclear factor of activated T cells c1 to the transcriptional control of immunoreceptor osteoclast-associated receptor but not triggering receptor expressed by myeloid cells-2 during osteoclastogenesis J Biol Chem 280 2005 32905